Oral rhGH (somatotropin)

• Global sales of all injectable rhGH products >$1.7 billion/yr
• Completed dosing of EMISPHERE® delivery agent and rhGH combination in FIM dose escalation study
• Data from both programs expected this year

Clinical Stage Partnerships

Previous slide

Next slide

Back to first slide

View graphic version